Cure My Disease

Don't miss your cure!

 Log in / Sign up

Asthma drug benralizumab put to the test in everyday life

NCT ID NCT05603845

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well benralizumab (Fasenra) works for people with severe eosinophilic asthma in real-world clinics across the Gulf, Latin America, and India. Researchers tracked 291 patients to see if their asthma control improved over time using a standard questionnaire. The goal was to provide practical evidence on how the drug performs outside of strict clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
benralizumab (Fasenra)
What this could lead to
If successful, this could confirm that benralizumab helps patients with severe eosinophilic asthma achieve better day-to-day control of their symptoms.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It does not test a new treatment, only how an existing one works in routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

291 people

The number who actually took part.

Started

Feb 2023

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will recruit 410 adult patients with confirmed severe eosinophilic asthma who meet all inclusion criteria and none of the exclusion criteria in 9 countries as described above. Approximately 6-8 hospitals per country will participate in the study which have previous experience with biologic treatment, can initiate treatment with benralizumab, and have a good oversight on the severe asthma population.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female patients aged 18 years or older with a physician's confirmed diagnosis of severe eosinophilic, uncontrolled asthma. 2. Severe uncontrolled eosinophilic asthma requiring high-dose\* inhaled corticosteroid plus long-acting β adrenoceptor agonist as maintenance treatment. 3. Patients who have been prescribed but not yet initiated treatment with benralizumab (Fasenra®) according to local approved prescribing information prior to signed informed consent. 4. Provision of the signed written informed consent form (ICF) indicating that they understand the purpose of the study and procedures required for participation. 5. Patients must be able and willing to read and comprehend written instructions and complete the paper PRO questionnaires required by the protocol. Exclusion Criteria: 1. Clinically important pulmonary diseases other than asthma including chronic obstructive pulmonary disease (as the main diagnosis), bronchiectasis, idiopathic pulmonary fibrosis, pulmonary hypertension, alpha-1-antitrypsin-deficiency, and malignancy of any kind (NB: the following conditions are permitted: nasal polyposis, allergic rhinitis, atopic dermatitis, non-idiopathic pulmonary fibrosis). 2. Currently enrolled in an interventional clinical study except patients being in parallel documented in a national asthma registry 3. An acute or chronic condition that, in the investigator's opinion, would limit the patients' ability to complete questionnaires or participate in this study or impact the interpretations of results. 4. Concurrent biologics for asthma are not allowed. Acceptable wash-out periods for other asthma biologics: ≥30 days from the last dose of the previous biologic. 5. Women who are currently pregnant, breastfeeding, or lactating

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe asthma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic asthma pulmonary eosinophilia T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Severe asthma

Contacts and locations

Locations

  • Research Site

    Bogotá, Colombia

  • Research Site

    Bucaramanga, Colombia

  • Research Site

    Ibague, Colombia

  • Research Site

    Pereira, Colombia

  • Research Site

    Santiago de los Caballeros, Dominican Republic

  • Research Site

    Santo Domingo, Dominican Republic

  • Research Site

    Ahmedabad, India

  • Research Site

    Ajmer, India

  • Research Site

    Chennai, India

  • Research Site

    Delhi, India

  • Research Site

    Hyderabad, India

  • Research Site

    Jaipur, India

  • Research Site

    Kolkata, India

  • Research Site

    Pune, India

  • Research Site

    Secundrabad, India

  • Research Site

    Vadodara, India

  • Research Site

    Sabah Al Salem, Kuwait

  • Research Site

    Muscat, Oman

  • Research Site

    Doha, Qatar

  • Research Site

    Jeddah, Saudi Arabia

  • Research Site

    Riyadh, Saudi Arabia

  • Research Site

    Abu Dhabi, United Arab Emirates

  • Research Site

    Al Ain City, United Arab Emirates

  • Research Site

    Dubai, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.